WuXi Biologics (Cayman) Inc. (WXIBF) revealed a profit for full year of RMB3.356 billion
The company's bottom line totaled RMB3.356 billion, or RMB0.78 per share. This compares with RMB3.399 billion, or RMB0.77 per share, last year.
Excluding items, WuXi Biologics (Cayman) Inc. reported adjusted earnings of RMB5.396 billion or RMB1.17 per share for the period.
The company's revenue for the period rose 9.6% to RMB18.675 billion from RMB17.034 billion last year.
WuXi Biologics (Cayman) Inc. earnings at a glance (GAAP) :
-Earnings: RMB3.356 Bln. vs. RMB3.399 Bln. last year.-EPS: RMB0.78 vs. RMB0.77 last year.-Revenue: RMB18.675 Bln vs. RMB17.034 Bln last year.
Chris Chen, CEO of WuXi Biologics, said: "Looking ahead, we anticipate accelerated and profitable growth in 2025 and beyond, driven by strong performances across all Research, Development, and Manufacturing platforms. With enhanced operational efficiencies, increasing adoption of next-generation technology platforms, and disciplined execution of our strategic initiatives, we are well-positioned to capture new opportunities and drive innovation."
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.